Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ARCA biopharma, Inc. (NASDAQ: ABIO).

Full DD Report for ABIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABIO)

NetworkNewsBreaks - ARCA Biopharma, Inc. (NASDAQ: ABIO) Posts Q1 Financial Results, Pipeline Progress; Presenting Clinical Trial Results at Heart Failure 2018 World Congress
ARCA biopharma (NASDAQ: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, recently reported financial results for the quarter ended March 31, 2018, as well as an update regarding its lead product ...
Source: NetworkNewsWire
Date: May, 14 2018 12:45
Today's Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing that the company will pre-specify new subgroup with the FDA and report phase 3 p...
Source: ACCESSWIRE IA
Date: May, 11 2018 08:20
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Phase 2B GENETIC-AF cl...
Source: GlobeNewswire
Date: May, 10 2018 08:30
Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks
Stock Research Monitor: APHB, APTO, and ABIO LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration . On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading ...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:15
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March ...
Source: GlobeNewswire
Date: May, 08 2018 16:15
ARCA Biopharma and Medtronic extend Gencaro clinical trial collaboration agreement
ARCA Biopharma (NASDAQ: ABIO ) announces that Medtronic (NYSE: MDT ) has extended the U.S., Canadian and European Clinical Trial Collaboration Agreement for an additional year to April 2019. More news on: ARCA biopharma, Inc., Medtronic plc, Healthcare stocks news, Stocks on the move, ...
Source: SeekingAlpha
Date: April, 23 2018 08:47
ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Medtronic, Inc. (NYSE:MDT) has extende...
Source: GlobeNewswire
Date: April, 23 2018 08:30
Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease
Stock Monitor: ARCA biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on Insmed Inc. (NASDAQ: INSM ). If you want access to this report all you need to do is sign up now by clicking the following...
Source: ACCESSWIRE IA
Date: April, 03 2018 07:20
ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update
WESTMINSTER, Colo., March 22, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended Decembe...
Source: GlobeNewswire
Date: March, 22 2018 16:30
Arca Biopharma Has One More Shot To Get It Right
Recently, Arca Biopharma ( ABIO ) announced results for its phase 2b trial treating patients with atrial fibrillation (AF) and left ventricular ejection fraction ((HFrEF)). The failed phase 2b trial data caused the stock to tumble by more than 60%. On the outset, the data as a totality of ...
Source: SeekingAlpha
Date: March, 01 2018 17:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.57510.58910.600.55328,062
2018-08-160.600.59980.61850.574193,740
2018-08-150.62160.59960.62160.597394116,596
2018-08-140.60590.62220.640.6059195,903
2018-08-130.660.61990.670.60537,302

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-174,037140,3102.8772Cover
2018-08-1621,34185,50624.9585Cover
2018-08-1511,04626,09442.3316Short
2018-08-1426,56692,75528.6410Cover
2018-08-1326,721218,29712.2407Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABIO.


About ARCA biopharma, Inc. (NASDAQ: ABIO)

Logo for ARCA biopharma, Inc. (NASDAQ: ABIO)

Not available

 

Contact Information

 

 

Current Management

  • Michael Bristow / CEO
  • Patrick Wheeler / CEO
  • Derek Cole / IR

Current Share Structure

  • Market Cap: $7,652,876 - 05/11/2018
  • Issue and Outstanding: 13,914,320 - 03/19/2018

 


Recent Filings from (NASDAQ: ABIO)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018

 

 


Daily Technical Chart for (NASDAQ: ABIO)

Daily Technical Chart for (NASDAQ: ABIO)


Stay tuned for daily updates and more on (NASDAQ: ABIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ABIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ABIO and does not buy, sell, or trade any shares of ABIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/